HLB Therapeutics Co.,Ltd. (KOSDAQ:115450)
South Korea
· Delayed Price · Currency is KRW 8,850.00
+190.00 (2.19%)
Apr 1, 2025, 3:30 PM KST
HLB Therapeutics Revenue
In the year 2024, HLB Therapeutics had annual revenue of 54.93B KRW with 4.45% growth. HLB Therapeutics had revenue of 16.46B in the quarter ending December 31, 2024, with 5.06% growth.
Revenue
54.93B
Revenue Growth
+4.45%
P/S Ratio
13.34
Revenue / Employee
590.67M
Employees
93
Market Cap
741.44B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.93B | 2.34B | 4.45% |
| Dec 31, 2023 | 52.59B | 10.19B | 24.03% |
| Dec 31, 2022 | 42.40B | -1.18B | -2.72% |
| Dec 31, 2021 | 43.59B | 656.63M | 1.53% |
| Dec 31, 2020 | 42.93B | -16.04B | -27.20% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,547.32B |
| Celltrion | 3,557.30B |
| ALTEOGEN | 102.85B |
| Yuhan | 2,067.79B |
| SK Biopharmaceuticals | 547.60B |
| HLB Co., Ltd. | 51.92B |
| Sam Chun Dang Pharm. | 210.92B |
| PharmaResearch | 350.12B |